<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03261375</url>
  </required_header>
  <id_info>
    <org_study_id>GL-CT-20170821</org_study_id>
    <nct_id>NCT03261375</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate Safety and Efficacy of a Renal Denervation System in Treatment of Hypertension</brief_title>
  <official_title>A Prospective, Multicentre, Randomized, Controlled Trial for Safety and Efficacy of a Renal Denervation System in Treatment of Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Golden Leaf MedTec Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Golden Leaf MedTec Co. Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre clinical trial to evaluate safety and efficacy of renal denervation&#xD;
      system in treatment of hypertension. Hypertensive patients who meet enrollment criteria will&#xD;
      be randomized into treatment group who will receive standardized drugs and renal denervation&#xD;
      treatments, or control group who will receive standardized drugs and a sham procedure (renal&#xD;
      artery angiography only without denervation). The patients will be monitored for blood&#xD;
      pressure changes and any adverse events for 6 months. The safety and efficacy of the device&#xD;
      will be evaluated by comparing blood pressure levels and adverse event episodes between the&#xD;
      two groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">August 27, 2017</start_date>
  <completion_date type="Anticipated">August 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>6 months</time_frame>
    <description>clinical blood pressure levels</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Primary Hypertension, Chronic Kidney Diseases (CKD) Hypertension</condition>
  <arm_group>
    <arm_group_label>Renal denervation (RDN) Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renal Denervation System</intervention_name>
    <description>A renal denervation system with a 6 electrodes-on-net structure catheter</description>
    <arm_group_label>Renal denervation (RDN) Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antihypertensive Agents</intervention_name>
    <description>Calcium channel blocker，Diuretic</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Renal denervation (RDN) Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Procedure</intervention_name>
    <description>Catheterization without renal denervation</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages of 18 to 65, male or female;&#xD;
&#xD;
          -  Patients who have been taking 2 or more anti-hypertensive drugs for at least 4 weeks,&#xD;
             with mean BP ≥150/90 mmHg based on 3 office blood pressure measurements, or ASBP≥135&#xD;
             mmHg based on 24 hr blood pressure monitoring;&#xD;
&#xD;
          -  Heart beats at rest ≥70 bpm&#xD;
&#xD;
          -  Confirmed diagnosis of primary hypertension or CKD hypertension;&#xD;
&#xD;
          -  Main renal artery, with or without accessary renal arteries;&#xD;
&#xD;
          -  Agrees to take part in the trial and signs the written, informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or plan to become pregnant, or Breastfeeding;&#xD;
&#xD;
          -  Renal artery abnormalities that are inappropriate for the procedure (renal stenosis&#xD;
             ≥50%, aneurysm, renal artery diameter &lt;4mm or length&lt;20mm) ;&#xD;
&#xD;
          -  Only one kidney or kidney transplant recipient&#xD;
&#xD;
          -  Prior renal artery interventional procedures or prior RDN treatment;&#xD;
&#xD;
          -  Any conditions affecting accuracy of blood pressure measurement, such as diameter of&#xD;
             upper arm too large for the cuff or severe arrhythmia;&#xD;
&#xD;
          -  Secondary hypertension other than CKD hypertension;&#xD;
&#xD;
          -  Pseudohypertension;&#xD;
&#xD;
          -  History of orthostatic hypotension;&#xD;
&#xD;
          -  Average systolic blood pressure (ASBP) &lt;135mmHg based on ambulatory 24 hours blood&#xD;
             pressure monitoring;&#xD;
&#xD;
          -  History of hospitalization for hypertensive emergencies within one year;&#xD;
&#xD;
          -  Type I diabetes;&#xD;
&#xD;
          -  Primary pulmonary hypertension;&#xD;
&#xD;
          -  Bleeding tendency or other coagulation related diseases;&#xD;
&#xD;
          -  Abnormal blood electrolytes levels;&#xD;
&#xD;
          -  History of stroke or transit ischemic attack (TIA) within 2 weeks;&#xD;
&#xD;
          -  Malignant tumor or end-stage illnesses;&#xD;
&#xD;
          -  Severe peripheral vascular diseases, aneurysm;&#xD;
&#xD;
          -  Acute coronary events within 2 weeks;&#xD;
&#xD;
          -  Patients who need assisted breathing with mechanical ventilation;&#xD;
&#xD;
          -  Acute or severe systemic infection;&#xD;
&#xD;
          -  Patients with pacemaker implantation;&#xD;
&#xD;
          -  Major surgery or trauma in 30 days before enrollment;&#xD;
&#xD;
          -  Plan to receive surgery or cardiovascular interventional procedures in 6 months;&#xD;
&#xD;
          -  Have been enrolled for other drug or device trial;&#xD;
&#xD;
          -  Known drug or alcohol dependency, unable to comprehend the trial protocol, unwilling&#xD;
             or unable to comply with follow-ups in accordance with the protocol;&#xD;
&#xD;
          -  Other conditions that deem unsuitable for the procedure, in the opinions of&#xD;
             investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yujie Zhou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Anzhen Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hua Q Yin, PhD</last_name>
    <phone>86-21-54868750</phone>
    <phone_ext>201</phone_ext>
    <email>huaqing.yin@goldenleafmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yujie Zhou, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xinchun Yang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Armed Police General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huiliang Liu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 3rd Affiliated Hospital Jilin University</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Yang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huaxi Hospital</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tianlei Cui, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 1st Affiliated Hospital Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinzi Su, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hanzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiang He, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanjing Gulou Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Biao Xu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gengshan Ma, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuqiang Zhang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 1st Affiliated Hospital Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pei Wang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 1st Affiliated Hospital Xinjian Medical University</name>
      <address>
        <city>Ürümqi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang Ma, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>August 21, 2017</study_first_submitted>
  <study_first_submitted_qc>August 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2017</study_first_posted>
  <last_update_submitted>August 24, 2017</last_update_submitted>
  <last_update_submitted_qc>August 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

